GLP-1 Market
LLY $1410.99 ▼ -0.5% NVO $40.45 ▲ +1.1% PFE $30.67 ▲ +0.5% VKTX $26.83 ▼ -1.6% KLRA $12.15 ▼ -5.5% GPCR $20.47 ▼ -6.4% RHHBY $60.68 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Formulation 1 for

Company
AstraZeneca
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 3, 2026

Trial details
  • Completed NCT NCT01848990

    CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

    Not yet reported Halozyme Therapeutics 456 participants Est. completion 2014-09 39 sites
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02193087

    Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

    Not yet reported Takeda 1002 participants Est. completion 2015-05-19 7 sites
    Other conditions: Dengue Fever
    View official trial listing →
  • Completed NCT NCT03929744

    A Study of LY3502970 in Healthy Participants

    Not yet reported Eli Lilly and Company 133 participants Est. completion 2020-11-02 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Not yet recruiting NCT NCT07911514

    A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234

    Not yet reported AstraZeneca 60 participants Est. completion 2027-05-04 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Formulation 1 for, Formulation 1 solution for injection, AZD9550+AZD6234, Formulation 2 solution for injection, Formulation 3 solution for injection, Formulation 4 solution for injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.